COMPANY

Neoolife

Neoolife is also developing solutions for the percutaneous treatment of heart valve disease, i.e., tricuspid valve regurgitation. From company website Source · Oct 13, 2026

Keywords: tissue engineering heart valve disease tricuspid valve insufficiency

Profile checked Oct 10, 2026

1NIH grants

NIH awards 1

Annual award amounts. Total $554K.

Apr 27, 2023 NIH award 1R41HL167502-01A1 FY2023: $553,838 awarded for that fiscal year; activity R41 (STTR); PI D'AMORE, ANTONIO; recipient as written: NEOOLIFE, INC., PITTSBURGH, PA. Development of a Biomimetic Stentless Pulmona source ↗